Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Stacie, Lambert"'
Autor:
Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, Philippe A. Cassier, Kiyotaka Yoh, Antoine Italiano, Victor Moreno, Katriina Peltola, Takashi Seto, Ryo Toyozawa, Daniel E. Afar, Stefan Englert, Philip Komarnitsky, Stacie Lambert, Apurvasena Parikh, Gregory Vosganian, Bo Gao
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100405- (2021)
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced
Externí odkaz:
https://doaj.org/article/e1966145ff134f7d8b7360173186cc8e
Autor:
Antoine Italiano, Minna Tanner, Gregory Vosganian, Philippe A. Cassier, Stacie Lambert, Rajeev M. Menon, Sven Mensing, Benjamin Engelhardt, Apurvasena Parikh, Drew W. Rasco, Stefan Englert, Anthony W. Tolcher, Bo Gao, Shunsuke Kondo, Sreeneeranj Kasichayanula, John D. Powderly, Daniel E. H. Afar, Anas Gazzah, Alexander I. Spira, Toshihiko Doi, Jason J. Luke, Diego Tosi
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 277-287 (2021)
Clinical and Translational Science
Clinical and Translational Science
Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb0ad4d1d6ee960228cef29fd21e688d
https://doi.org/10.1111/cts.12855
https://doi.org/10.1111/cts.12855
Autor:
Philippe A. Cassier, Sylvie Rottey, Maria de Miguel, Stefan Englert, Michael Millward, Hans Prenen, Stacie Lambert, Victor Moreno, Takashi Seto, Emiliano Calvo, Tuomo Alanko, Alexander I. Spira, Lydia Warburton, Philip Komarnitsky, Katriina Peltola, Anas Gazzah, Bo Gao, Apurvasena Parikh, Shunsuke Kondo, Kiyotaka Yoh, Antoine Italiano, Ryo Toyozawa, Gregory Vosganian, Daniel E. H. Afar
Publikováno v:
Cancer Treatment and Research Communications
Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100405-(2021)
CANCER TREATMENT AND RESEARCH COMMUNICATIONS
Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100405-(2021)
CANCER TREATMENT AND RESEARCH COMMUNICATIONS
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3eccfd7327084c34dece2733d664ed1
https://pubmed.ncbi.nlm.nih.gov/34329846
https://pubmed.ncbi.nlm.nih.gov/34329846
Autor:
Naval Guastad Daver, Don A. Stevens, Jing-Zhou Hou, Takahiro Yamauchi, Yakir Moshe, Chun Yew Fong, Angela Marzocchetti, Ryan Adamec, Maulik Patel, Stacie Lambert, Kevin Wu, Christoph Röllig
Publikováno v:
Journal of Clinical Oncology. 40:TPS7067-TPS7067
TPS7067 Background: Despite treatment advances, pts with AML or higher-risk MDS who are ineligible for standard intensive treatments still have poor survival, highlighting the need for novel therapies. Overexpression of CD47 is common in leukemic ste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a834be5dc7195714123ebc6ca33ff6c1
https://doi.org/10.1200/jco.2022.40.16_suppl.tps7067
https://doi.org/10.1200/jco.2022.40.16_suppl.tps7067
Publikováno v:
Cancer Research. 81:153-153
INTRODUCTION: Olink is a high-throughput targeted biomarker platform based on Proximity Extension Assay (PEA) technology using oligonucleotide-labeled antibody pairs. At AbbVie RWC, we have primarily utilized the 96-plex Immune-Oncology (IO) panel me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71443a7e24df4700b908e49937949c05
https://doi.org/10.1158/1538-7445.am2021-153
https://doi.org/10.1158/1538-7445.am2021-153
Autor:
Jayaprakash Kotha, Michelle Graham, Lisa K. Jennings, Stacie Lambert, Sridevi Kotha, Juan M Cardenas, Kinjal Hew
Publikováno v:
Cancer Research. 81:1308-1308
Introduction: GARP is a cell surface protein expressed post activation on regulatory T-cells (Treg), monocytes, B cells, and platelets. GARP binds to latent transforming growth factor beta (TGF-β1) and regulates the release of active TGF-β1. TGF-β
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b6fa1305cf5e82ff0fe7c78608491b2
https://doi.org/10.1158/1538-7445.am2021-1308
https://doi.org/10.1158/1538-7445.am2021-1308
Autor:
Jordi Bruix, Talia Golan, Gregory Vosganian, Kathy D. Miller, Anthony W. Tolcher, Susan Lacy, Satwant Lally, Toshio Shimizu, Arjun Vasant Balar, Stacie Lambert, John D. Powderly, Martha Elizabeth Blaney, Xiaowen Guan, Rachel S Leibman, Patricia LoRusso, Albiruni Ryan Abdul Razak, Loren S. Michel
Publikováno v:
Cancer Research. 81:CT207-CT207
Background Glycoprotein-A repetitions predominant (GARP) regulates membrane-bound transforming growth factor β1 (TGFβ1), an immunosuppressive cytokine. ABBV-151 is a first-in-class monoclonal antibody (mAb) that binds to the GARP-TGFβ1 complex and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::364f5a4c8f04997c92b89ba73dc652f9
https://doi.org/10.1158/1538-7445.am2021-ct207
https://doi.org/10.1158/1538-7445.am2021-ct207
Autor:
M. Nagasaka, Martha Elizabeth Blaney, T. Dai, J. Grewal, Stacie Lambert, Y. Li, Missak Haigentz, Aru Panwar, C. Maurice-Dror, Daniel Da Costa, I. Moreno, Maulik Patel, Ari Rosenberg, Jordan Berlin, C. Le Tourneau, I. Gluck, Michael A. McDevitt, Xiuning Le, Kathryn A. Gold, Maura L. Gillison
Publikováno v:
Annals of Oncology. 31:S685
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cab1a987d6fc2b2ea1723583aee482a2
https://doi.org/10.1016/j.annonc.2020.08.1090
https://doi.org/10.1016/j.annonc.2020.08.1090
Autor:
Kathy D. Miller, Stacie Lambert, Albiruni Ryan Abdul Razak, Satwant Lally, Talia Golan, Toshio Shimizu, Arjun Vasant Balar, Jordi Bruix, Anthony W. Tolcher, Patricia LoRusso, Rachel S Leibman, Susan Lacy, John D. Powderly, Martha Elizabeth Blaney, Loren S. Michel, Gregory Vosganian, X. Guan
Publikováno v:
Annals of Oncology. 31:S499
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2723b40ae7fe5202ceb946dcbe5bc16
https://doi.org/10.1016/j.annonc.2020.08.710
https://doi.org/10.1016/j.annonc.2020.08.710
Autor:
Tolga Turan, David Masica, Chun Zhang, Catherine Tribouley, Gregory Vosganian, Claire J. Guo, Stefan Englert, Robert T. McLaughlin, Stacie Lambert, Daniel E. H. Afar
Publikováno v:
Cancer Research. 80:4464-4464
Background: Programmed cell death 1 (PD-1) is a receptor upregulated on activated lymphocytes that mediates a dominant-negative checkpoint signal limiting antigen receptor-driven cellular activation. PD-1 immune checkpoint inhibitors have shown durab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4f44ae785ddbac576be2421beb9f7ed
https://doi.org/10.1158/1538-7445.am2020-4464
https://doi.org/10.1158/1538-7445.am2020-4464